H.C. Wainwright raised the firm’s price target on BioLineRx to $21 from $19 and keeps a Buy rating on the shares after the FDA approved Aphexda in combination with filgrastim to mobilize hematopoetic stem cells for collection and subsequent autologous transplantation in patients with multiple myeloma.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BLRX:
- Largest borrow rate increases among liquid names
- BioLineRx announces FDA approval of APHEXDA/filgrastim combination
- Biotech Alert: Searches spiking for these stocks today
- BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
- Options Volatility and Implied Earnings Moves Today, August 30, 2023
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue